Bayer AG (BAYN.XE) said Monday that it is seeking approval from the European Medicines Agency to market a new arterial disease treatment involving the use of its blood-thinning drug Xarelto.
The German company said that the application is based on the results of a phase 3 study showing that aspirin combined with Xarelto--also known as rivaroxaban--reduced the risk of stroke, cardiovascular death and heart attacks in coronary and peripheral artery disease patients by 24% compared with aspirin alone.
Continue Reading Below
Bayer expects to make a parallel filing in the U.S. by the end of the year.
Coronary artery disease and peripheral artery disease are caused by a buildup of plaque in the arteries. Patients with these conditions are at risk of thrombotic events that may lead to disability, loss of limb and death.
Write to Marc Navarro Gonzalez at firstname.lastname@example.org
(END) Dow Jones Newswires
November 06, 2017 03:52 ET (08:52 GMT)